Overview

A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis

Status:
Completed

Trial end date:
2019-08-08

Target enrollment:

Participant gender:

Summary

This is a Phase 1b, open-label, study to assess the effects of AK002, given as monthly intravenous infusion for 6 doses at up to 3 mg/kg.

Phase:

Phase 1

Details

Lead Sponsor:

Allakos, Inc.